• About us
• Contact

Advertisement

Organisation › Details

ITM (Group)

ITM, a privately held radiopharmaceutical biotech company founded in 2004, is dedicated to providing the most precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and our partners through excellence in development, production and global supply. With patient benefit as the driving principle for all we do, ITM is advancing a broad pipeline combining its superior radioisotopes with targeting molecules to create precision oncology treatments. ITM is leveraging its leadership and nearly two decades of radioisotope expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better. *

 

	Start	2004-01-01 established
	Industry	RADIOPHARMACEUTICAL (RPT)
	Industry 2	radionucleotide therapy
	Person	Schuster, Steffen (ITM Isotopen Technologien München 201603 CEO)
	Person 2	Scharrer, Nicola (ITM Isotopen Technologien München 201603 Head of Marketing)
	Region	Garching
	Country	Germany
	Street	1 Lichtenbergstr.
	City	85748 Garching
	Tel	+49-89-329-8986-600
		Address record changed: 2022-09-18
Basic data	Employees	n. a.
		* Document for »About Section«: ITM Isotopen Technologien München AG. (5/4/21). "Press Release: ITM Establishes Subsidiary in Shanghai to Accelerate Introduction of Its Precision Oncology Portfolio in China".
		Record changed: 2024-12-29

Advertisement

More documents for ITM (Group)

• [1] ITM Isotope Technologies Munich SE. (6/20/24). "Press Release: ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth". Garching....
• [2] ITM Isotope Technologies Munich SE. (6/6/24). "Press Release: ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing". Garching....
• [3] ITM Isotope Technologies Munich SE. (2/1/24). "Press Release: ITM Obtains Manufacturing License in the U.S.". Garching & Princeton, NJ....
• [4] ITM Isotope Technologies Munich SE. (1/30/24). "Press Release: ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program". Garching & Vancouver, BC....
• [5] ITM Isotope Technologies Munich SE. (1/16/24). "Press Release: ITM Appoints Dr. Mark Harfensteller as Member of Its Executive Board". Garching....
• [6] ITM Isotope Technologies Munich SE. (1/4/24). "Press Release: ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site". Garching....
• [7] ITM Isotope Technologies Munich SE. (12/21/23). "Press Release: ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference". Garching....
• [8] ITM Isotope Technologies Munich SE. (12/14/23). "Press Release: ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics". Garching....
• [9] ITM Isotope Technologies Munich SE. (7/31/23). "Press Release: ITM and Point Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177". Garching & Indianapolis, IN....
• [10] ITM Isotope Technologies Munich SE. (6/13/23). "Press Release: ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer". Neufahrn, Garching & Munich....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.